AOI announces skull base tumour centre for cancer treatment

American Oncology Institute (AOI), a city-based chain of cancer hospitals, today announced the launch of comprehensive Centre for Skull Base Tumour for treatment of cancerous and non-cancerous diseases. 

According to Dr M Babaiah, Medical Director, American Oncology Institute, majority of the skull base tumours spread very fast, making patients report for treatment in advanced stages of the disease, which results in delay of timely and quality medical treatment. 

 "With the comprehensive Centre for Skull Base Tumor, we would be able to meet the demand for precision-driven cancer treatment," he said. 

Dr Babaiah, who is leading the Centre for Skull Base Tumour along with specialised team of experts, said skull base tumours grow on the bones of the skull that form the bottom of the head and the body ridge behind the nose and eyes. 
Skull base tumours present unique challenges because of their relative rarity, typically deep location, close proximity to critical neurovascular structures, said Consultant and Chief of Surgical Oncology (Head & Neck) Dr Sashikanth Jonnalagadda. 

"Skull base is a complex anatomical area at the base of brain and upper end of the neck. As several vital structures traverse through this complex region, surgery has always been a challenge. "Now with advent of new surgical techniques and state of art equipment like computer aided surgery, high definition endoscopes and high-speed nasal drills, a team of surgeons comprising ENT and neurosurgeon can now deal with most of the diseases of this complex area in a safe and minimally invasive way," Dr Jonnalagadda said. 

AOI was founded by a team of oncologists at the University of Pittsburgh Medical Centre in US.
Source:http://www.business-standard.com/article/pti-stories/aoi-announces-skull-base-tumour-centre-for-cancer-treatment-117082201111_1.html

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that BMTP
Read more